title: Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
abstract: Beta-lactams enhance the killing activity of vancomycin. Due to structural and mechanistic similarities between vancomycin and telavancin, we investigated the activity of telavancin combined with nafcillin and imipenem compared to the known synergistic combination of telavancin and gentamicin. Thirty strains of Staphylococcus aureus, 10 methicillin-susceptible S. aureus (MSSA), 10 methicillin-resistant S. aureus (MRSA), and 10 heterogeneously vancomycin-intermediate S. aureus (hVISA), were tested for synergy by time-kill methodology. Six strains (2 each of MSSA, MRSA, and hVISA) were further evaluated in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated regimens of 10 mg/kg of body weight of telavancin once daily alone and combined with 2 g nafcillin every 4 h, 500 mg imipenem every 6 h, or 5 mg/kg gentamicin once daily over 72 h. In the synergy test, 67% of strains displayed synergy with the combination of telavancin and gentamicin, 70% with telavancin and nafcillin, and 63% with telavancin and imipenem. In the PK/PD model, the activities of all three combinations against MRSA and hVISA were superior to all individual drugs alone (P ≤ 0.002) and were similar to each other (P ≥ 0.187). The activities of all three combinations against MSSA were generally similar to each other except for one strain where the combination of telavancin and imipenem was superior to all other regimens (P ≤ 0.011). The activity of the combination of telavancin and beta-lactam agents was similar to that of telavancin and gentamicin against S. aureus, including resistant strains. Because beta-lactam combinations are less likely to be nephrotoxic than telavancin plus gentamicin, these beta-lactam combinations may have clinical utility.
authors.affiliation: Northeastern University, Bouvé College of Health Sciences, School of Pharmacy, Boston, Massachusetts, USA. s.leonard@neu.edu
authors.forename: Steven N
authors.initials: SN
authors.lastname: Leonard
authors.forename: Megan E
authors.initials: ME
authors.lastname: Supple
authors.forename: Ronak G
authors.initials: RG
authors.lastname: Gandhi
authors.forename: Meghna D
authors.initials: MD
authors.lastname: Patel
mesh_terms: D000617:Aminoglycosides / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D009254:Nafcillin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance / Q000187:drug effects
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D000077427:Lipoglycopeptides; D009254:Nafcillin; D015378:Imipenem; C487637:telavancin
references.citation: J Antimicrob Chemother. 1990 Apr;25(4):679-87
references.pmid: 2351627
references.citation: Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
references.pmid: 15699079
references.citation: Antimicrob Agents Chemother. 1999 Jul;43(7):1747-53
references.pmid: 10390234
references.citation: Antimicrob Agents Chemother. 2010 May;54(5):2201-5
references.pmid: 20160048
references.citation: Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55
references.pmid: 10390201
references.citation: Clin Infect Dis. 2011 Jan 1;52(1):31-40
references.pmid: 21148517
references.citation: J Clin Microbiol. 2008 Sep;46(9):2950-4
references.pmid: 18632899
references.citation: PLoS One. 2012;7(7):e42103
references.pmid: 22848719
references.citation: J Antimicrob Chemother. 1985 Jan;15 Suppl A:125-30
references.pmid: 3980323
references.citation: J Antimicrob Chemother. 2010 May;65(5):1015-8
references.pmid: 20200036
references.citation: Antimicrob Agents Chemother. 2005 Jul;49(7):2735-45
references.pmid: 15980344
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72
references.pmid: 15561842
references.citation: Clin Infect Dis. 2008 Mar 1;46(5):647-55
references.pmid: 18225981
references.citation: Clin Infect Dis. 2009 Mar 15;48(6):713-21
references.pmid: 19207079
references.citation: Clin Infect Dis. 2008 Jun 1;46(11):1683-93
references.pmid: 18444791
references.citation: Br J Clin Pharmacol. 1984 Aug;18(2):183-93
references.pmid: 6593092
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references.pmid: 21258094
references.citation: PLoS One. 2012;7(8):e41870
references.pmid: 22916113
references.citation: Antimicrob Agents Chemother. 2010 Aug;54(8):3161-9
references.pmid: 20547804
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3315-20
references.pmid: 18591266
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):867-73
references.pmid: 21078943
references.citation: J Infect Dis. 2009 Nov 1;200(9):1355-66
references.pmid: 19811099
references.citation: J Antimicrob Chemother. 2005 Jul;56(1):91-6
references.pmid: 15890721
references.citation: J Antimicrob Chemother. 2010 Aug;65(8):1792-8
references.pmid: 20511366
references.citation: J Clin Microbiol. 2010 Mar;48(3):894-9
references.pmid: 20089758
references.citation: Clin Infect Dis. 2004 Nov 1;39(9):1267-84
references.pmid: 15494903
references.citation: N Engl J Med. 2006 Aug 17;355(7):653-65
references.pmid: 16914701
references.citation: J Infect Dis. 1970 Sep;122:Suppl:S9-13
references.pmid: 5460296
references.citation: Arch Intern Med. 1970 Apr;125(4):685-90
references.pmid: 5437893
references.citation: Antimicrob Agents Chemother. 1973 May;3(5):559-61
references.pmid: 4790611
references.citation: J Infect Dis. 2009 Mar 1;199(5):619-24
references.pmid: 19199552
references.citation: J Antimicrob Chemother. 2005 Dec;56(6):1163-5
references.pmid: 16234333
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2928-33
references.pmid: 19414568
references.citation: Clin Infect Dis. 2011 Feb 1;52(3):e18-55
references.pmid: 21208910